Efficacy and Safety of Newly Developed Korean Continuous Positive Airway Pressure Treatment in Patients with Obstructive Sleep Apnea Syndrome.
- Author:
Jong In JEONG
1
;
Jung Joo LEE
;
Seonwoo KIM
;
Su Jin KIM
;
Sang Duk HONG
;
Seung Kyu CHUNG
;
Hun Jong DHONG
;
Hojoong KIM
;
Hyo Yeol KIM
Author Information
- Publication Type:Original Article
- Keywords: OSAS; AHI; Efficacy; Safety; Newly developed Korean CPAP
- MeSH: Apnea; Continuous Positive Airway Pressure*; Humans; Methods; Physical Examination; Polysomnography; Respiratory Function Tests; Sleep Apnea, Obstructive*
- From:Journal of Rhinology 2016;23(1):6-16
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND AND OBJECTIVES: Obstructive sleep apnea syndrome(OSAS) is characterized by repeated apnea, hypopnea, and micro-arousals during sleep. Among various treatment modalities of OSAS, continuous positive airway pressure(CPAP) treatment is the most effective and successful. The aim of this study was to compare efficacy and safety of newly developed Korean CPAP with standard CPAP in OSAS patients. MATERIALS AND METHOD: In total, 20 of 26 recruited OSAS patients completed the study. All subjects first used the standard CPAP for 4 weeks. After an at least 2 week wash-out period, the subjects used the newly developed CPAP for 4 weeks. Polysomnography, questionnaires associated with sleep, lipid profile, pulmonary function test, cardiac marker, and physical examinations were evaluated at baseline and were followed-up after each treatment. RESULTS: After treatment with the newly developed CPAP, the apnea-hypopnea index was decreased from 53.2/hr to 2.5/hr and was equivalent to that of the standard CPAP. Most of the changes in questionnaire scores, laboratory findings, and physical examinations after newly developed CPAP treatment were equivalent to those with standard CPAP. No serious adverse events were observed during the study. CONCLUSION: The efficacy and safety of a newly developed CPAP are equivalent to those of standard CPAP in OSAS patients.
